DURAFIBER Ag Post-Market Clinical Follow-Up

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-12

Study Completion Date

2019-06-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to evaluate the performance of DURAFIBER Ag and to assess how many bacteria are present in infected wounds over an 8 week period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of the Clinical Performance of Biatain Fiber Ag on Venous Leg Ulcers

NCT05873257

Venous Leg Ulcer

COMPLETED NA

An Open, Non-comparative, Multicenter Investigation to Evaluate the Safety and Performance of Exufiber Ag+, a Gelling Fiber Silver Dressing, When Used in Medium to High Exuding Chronic Wounds

NCT05494450

Pressure Ulcer Diabetic Foot Ulcer Venous Leg Ulcer

TERMINATED NA

Long-Term Follow-Up to the DEVO Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers

NCT01891760

Venous Leg Ulcer

COMPLETED PHASE3

Clinical Trial to Evaluate the Efficacy, Tolerance and Acceptability of URGO Dressing vs a Hydrofibre in the Local Management of Venous or Predominantly Venous Mixed Leg Ulcers.

NCT01449422

Varicose Ulcer

COMPLETED PHASE4

AQUACEL® Ag Dressing and Urgotul® Silver Dressing on Healing of Chronic Venous Leg Ulcers

NCT01084577

Leg Ulcer

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of the study is to evaluate the performance of DURAFIBER Ag and to assess how many bacteria are present in infected wounds over an 8 week period.

DURAFIBER Ag is a commercially available absorbent, non-woven, silver-containing antimicrobial dressing for use on a variety of exuding wounds and is widely used in routine clinical practice within the UK.

The primary outcome will be the quantitative reduction in bacterial load, based on a wound biopsy, from baseline to week 8. Secondary objectives will include the quantitative reduction in bacterial load, based on biopsy, from initial assessment to week 4, and the semi-quantitative reduction in bacterial load, based on swab analysis, from baseline to weeks 4 and 8. Additionally dressing performance measures will be assessed as well as all adverse events and device deficiencies.

In total 20 evaluable participants with an infected venous leg ulcer will be recruited into the trial. All participants will have their wound dressed using DURAFIBER Ag and will be followed-up for 8 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wounds and Injuries Venous Leg Ulcer Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Antimicrobial Dressing

Group Type EXPERIMENTAL

DURAFIBER Ag

Intervention Type DEVICE

DURAFIBER Ag is a commercially available absorbent, non-woven, silver-containing antimicrobial dressing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DURAFIBER Ag

DURAFIBER Ag is a commercially available absorbent, non-woven, silver-containing antimicrobial dressing

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject or must provide written informed consent.
* Subjects must be at least eighteen (18) years of age.
* Willing and able to make all required study visits.
* Able to follow instructions.
* Subjects must have a VLU, an ankle brachial pressure index (ABPI) taken within the last 28 days of 0.8-1.3, and must be treated with compression therapy.
* The subject must have a wound with an area ≥ 2cm².
* The subject's wound must have moderate or high exudate levels.
* The subject's reference wound must, in the opinion of the Healthcare Professional, show signs of infection warranting treatment with DURAFIBER Ag.
* In the clinician's opinion the subject's wound has an initial bacterial count of \> 104 cfu/g (which will be confirmed following the initial wound biopsy).

-The subject's wound has a confirmed initial bacterial count of \> 104 cfu/g

Exclusion Criteria

* Contraindications or hypersensitivity to the use of the DURAFIBER Ag, ancillary products or their components (e.g. known sensitivity to silver).
* Participation in the treatment period of another clinical trial within thirty (30) days of the date of consent.
* Subjects with skin features (e.g. tattoos, skin colour, pre-existing scarring) which, in the opinion of the Investigator, will interfere with the study assessments.
* Subjects receiving topical antimicrobials or oil-based products (such as petrolatum) at the reference wound surface.
* Subjects being treated with immunosuppressive drugs or corticosteroids.
* Subjects who have participated previously in this clinical trial and who have healed or been withdrawn.
* Subjects with a known history of poor compliance with medical treatment.
* Subjects with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No